These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22918879)

  • 1. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.
    Xu CF; Xue Z; Bing N; King KS; McCann LA; de Souza PL; Goodman VL; Spraggs CF; Mooser VE; Pandite LN
    Ann Oncol; 2012 Sep; 23(9):2470-2471. PubMed ID: 22918879
    [No Abstract]   [Full Text] [Related]  

  • 2. Rhabdomyolysis in prostate cancer--caution in prescribing cyproterone acetate with statins.
    Ahamed E; Bissett D
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):528-9. PubMed ID: 15630845
    [No Abstract]   [Full Text] [Related]  

  • 3. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.
    Tomlinson B; Hu M; Lee VW; Lui SS; Chu TT; Poon EW; Ko GT; Baum L; Tam LS; Li EK
    Clin Pharmacol Ther; 2010 May; 87(5):558-62. PubMed ID: 20130569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of rosuvastatin and simvastatin on myocardial high-energy phosphate metabolism.
    Frick M; Klug G; Zwick RH; Schocke MF; Jaschke W; Pachinger O; Metzler B
    Int J Cardiol; 2011 Apr; 148(1):112-4. PubMed ID: 21315463
    [No Abstract]   [Full Text] [Related]  

  • 6. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
    Rosen JB; Jimenez JG; Pirags V; Vides H; Hanson ME; Massaad R; McPeters G; Brudi P; Triscari J
    Diab Vasc Dis Res; 2013 May; 10(3):277-86. PubMed ID: 23288881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib.
    Bukowski RM; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
    Kendra KL; Plummer R; Salgia R; O'Brien ME; Paul EM; Suttle AB; Compton N; Xu CF; Ottesen LH; Villalona-Calero MA
    Mol Cancer Ther; 2015 Feb; 14(2):461-9. PubMed ID: 25504632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
    Xu CF; Johnson T; Wang X; Carpenter C; Graves AP; Warren L; Xue Z; King KS; Fraser DJ; Stinnett S; Briley LP; Mitrica I; Spraggs CF; Nelson MR; Tada H; du Bois A; Powles T; Kaplowitz N; Pandite LN
    Clin Cancer Res; 2016 Mar; 22(6):1371-7. PubMed ID: 26546620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
    Prescrire Int; 2004 Aug; 13(72):132-4. PubMed ID: 15532136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
    Davidson MH; Stein EA; Hunninghake DB; Ose L; Dujovne CA; Insull W; Bertolami M; Weiss SR; Kastelein JJ; Scott RS; Campodónico S; Escobar ID; Schrott HG; Bays H; Stepanavage ME; Wu M; Tate AC; Melino MR; Kush D; Mercuri M; Mitchel YB;
    Nutr Metab Cardiovasc Dis; 2000 Oct; 10(5):253-62. PubMed ID: 11213534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PharmGKB summary: pazopanib pathway, pharmacokinetics.
    Thorn CF; Sharma MR; Altman RB; Klein TE
    Pharmacogenet Genomics; 2017 Aug; 27(8):307-312. PubMed ID: 28678138
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
    Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin for the treatment of hypercholesterolemia.
    Culhane NS; Lettieri SL; Skae JR
    Pharmacotherapy; 2005 Jul; 25(7):990-1000. PubMed ID: 16006277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of simvastatin for high-risk hypercholesterolemia.
    Mölgaard J; Wärjerstam-Elf S; Olsson AG
    Am J Cardiol; 1999 Apr; 83(7):1043-8. PubMed ID: 10190517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Oct; 22(10):2037-9. PubMed ID: 17022863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.